Abilify Linked to Compulsive Behavior
Popular Medication May Cause Pathological Gambling, Compulsive Shopping, and Binge Eating
According to the FDA, the top-selling antipsychotic in the Unites States, Abillify (aripiprazole), has been linked via medical studies to compulsive gambling, compulsive shopping, hyper-sexuality and binge eating.
Abilify is an anti-psychotic drug developed by Otsuka Pharmaceutical Co., LTD and Otsuka America Pharmaceutical, Inc. Abilify entered the US market in 2002 after co-opting its development with pharmaceutical manufacturer Bristol-Myers Squibb. Shortly after introduction, Abilify became the top-seller in the anti-psychotic medication class and was often prescribed for schizophrenia, bipolar disorder, depression, autism spectrum disorders and Parkinson’s disease.
Although completely aware of these potential life-ruining side-effects which could result in substantial financial, mental and/or physical damages, it was not until the FDA announced that the Abilify warnings would be changed that Bristol-Myers Squibb modified its US packaging warnings and risk alerts, circa August 2016. The change in the warning states:
Post-marketing case reports suggest that patients can experience intense urges, especially for gambling, and the inability to control these urges while taking Abilify. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or intense gambling urges or other urges while being treated with aripiprazole (Abilify). Urges were reported to have stopped when the dose was reduced or the medication (Abilify) was discontinued. Compulsive behaviors may result in harm to the patient and others if not recognized.
Presently, Abilify lawsuits filed against Bristol-Myers Squibb and Otsuka allege that the uncontrollable, compulsive behaviors were known prior to the 2016 label change. One lawsuit filed on July 25, 2016, in the United States District Court for the District of Massachusetts, states that the European Medicines Agency required Otsuka to warn patients and the medical community in Europe that the use of Abilify includes the risk of pathological gambling. Also, the European label includes additional language under the “Undesirable effects” section stating “Psychiatric disorders: agitation, nervousness, pathological gambling, suicide attempt, suicidal ideation and completed suicide.”
If you or a loved one has taken Abilify and struggled with uncontrollable behavior like compulsive gambling and binge eating or if you have amassed a gambling debt due to an uncontrollable urge to gamble, you may have the option to participate in a lawsuit against Bristol-Myers Squibb and Otsuka Pharmaceutical Company. Contact our attorneys today to learn more about your legal rights. There is never a fee unless we collect for you.
Read the court MDL transfer order here.